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Discussion
• Very preterm infants require mydriatic eye 
drops in preparation for retinopathy of 
prematurity (ROP) screening.
• In New Zealand and Australia,  approx. 3,500 
premature infants/year are screened for ROP.
• 66% of infants screened don’t have ROP. 
Survey
• A Survey Monkey questionnaire was emailed 
to selected nursing staff at Neonatal Intensive 
Care Units (NICU).
• Staff were identified in the Directory of NICU 
within Australia and New Zealand 2017 
register.
• The target survey population were staff who 
administer the mydriatic medicines for ROP 
screening.
Systematic review
• 10 papers were identified (all small sample size).  
• Nine studies compared various combinations of 
phenylephrine and cyclopentolate and/or 
tropicamide.
• Irrespective of the combination of medications, 
pupil dilation results were above 5mm.
• 2014 Vicente et al results show a non-
statistically difference in pupil dilation in all 
regimens (Figure 1).
• 5 studies noted an increase in blood pressure.
• 1 study noted an increase in feed intolerance.
• Very often skin blanching apnoea,  
tachycardia, feed intolerance 
occurred (Figure 2).
• Sometimes hypertension, tachycardia, 
apnoea, feed intolerance, skin 
blanching occurred  (Figure 2).
• Rarely NEC, HTN, tachyapnoea, feed 
intolerance, seizure, skin blanching 
occurred. 
• Nursing staff reported seeing 
additional adverse effects following 
mydriatic administration; bradycardia, 
abdominal distension and death.
• A robust data set  is lacking.
• Neonatal nurses associate mydriatics with 
significant harm, including NEC and death.
• Side effects are seen if systemic or 
transdermal absorption occurs.  
• Consequential harm caused by mydriatic 
medicines used in ROP screening should not 
be occurring.
• A sufficiently powered data set is required to a) establish low 
dose efficacy of mydriatic medicines, b) incidence of adverse 
drug effects, with a focus on the most vulnerable infants.
Figure 2.  Reported adverse effects, by nursing staff, following 
mydriatic eye drop administration
Survey
• 46 neonatal nurses from Australia 
(n= 30) and New Zealand (n= 16) 
participated in the survey.
• 11 different mydriatic regimens 
were identified (Tables 1).
• Regimens F and G were the most 
common regimens (n=18).
• Phenylephrine dosing ranged from 
70 µg to 1950 µg (28 fold 
difference).
• Cyclopentolate dosing ranged from 
14 µg to 260 µg (18 fold difference).
• Tropicamide dosing ranged from 
260 µg to 780 µg (3 fold difference).
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Systematic review
• To systematically review literature for efficacy 
and safety of mydriatic regimens used in ROP 
screening.
Survey
• To determine the variation of NICU mydriatic 
regimens within New Zealand and Australia.
• To estimate the frequency of adverse drug 
events after mydriatic administration.
Systematic review
• Two review authors independently carried out 
the literature search.
• Publications that evaluated efficacy and safety 
of mydriatic regimens, in premature infants, 
were included in the review. 
• MEDLINE via Ovid, PubMed, Web of Science, 
Cochrane Library and Cochrane Neonatal 































































V e r y  O f t e n
S o m e t i m e s
R a r e ly
N e v e r
Regimen
Phenylephrine
total dose µg (%*)
Cyclopentolate 





A 70 (1%) 14 (0.2%) 1 7
B 520 (1%) 104 (0.2%) 2 35
C 260 (1.25%) 65 (0.25%) 1 35
D 87.5 (1.25%) 17.5 (0.25%) 1 7
E 650 (2.5%) 65 (0.25%) 1 35
F 650 (2.5%) 130 (0.5%) 1 35
G 1300 (2.5%) 260 (0.5%) 2 35
Regimen
Phenylephrine
total dose µg (%*)
Tropicamide





H 1300 (2.5%) 260 (0.5%) 2 35
I 1950 (2.5%) 390 (0.5%) 3 35
J 1300 (2.5%) 520 (1%) 2 35
K 1950 (2.5%) 780 (1%) 3 35
*concentration expressed as percentage
Figure 1.  Vicente et al 1 Mean pupil size for 
phenylephrine 1% and cyclopentolate 0.2%
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N o  d r o p s
1  d r o p
2  d r o p s
3  d r o p s
• Results from pilot studies suggest that there is very little benefit in 
administering larger doses when smaller doses are effective.
Table 1.  Reported mydriatic regimens in New Zealand and 
Australia. 
